Extrawell Pharmaceutical Holdings (HKSE:00858) Notes Receivable: HK$ Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Extrawell Pharmaceutical Holdings Notes Receivable?

Extrawell Pharmaceutical Holdings HKSE:00858 Notes Receivable is HK$ Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Extrawell Pharmaceutical Holdings's Notes Receivable for the quarter that ended in Mar. 2026 was HK$ Mil.

Extrawell Pharmaceutical Holdings Notes Receivable Related Terms

Extrawell Pharmaceutical Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Extrawell Pharmaceutical Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extrawell Pharmaceutical Holdings Notes Receivable Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Extrawell Pharmaceutical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Extrawell Pharmaceutical Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$ Mil mean?
Extrawell Pharmaceutical Holdings (HKSE:00858) has a Notes Receivable of HK$ Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Extrawell Pharmaceutical Holdings and its competitors.
Is Extrawell Pharmaceutical Holdings' Notes Receivable too high?
Extrawell Pharmaceutical Holdings' current Notes Receivable is HK$ Mil.
How does Extrawell Pharmaceutical Holdings' Notes Receivable compare to ZTS?
Extrawell Pharmaceutical Holdings' Notes Receivable of HK$ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Extrawell Pharmaceutical Holdings and its competitors. Extrawell Pharmaceutical Holdings's current Notes Receivable is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extrawell Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Extrawell Pharmaceutical Holdings (HKSE:00858) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.05, compared to a current price of HK$0.08 — trading 68% above its estimated fair value. The current Notes Receivable is HK$ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Extrawell Pharmaceutical Holdings (HKSE:00858), the current Notes Receivable is HK$ Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Extrawell Pharmaceutical Holdings Business Description

Address 979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.